Peterson Wealth Management Trims Stake in Eli Lilly and Company $LLY

Peterson Wealth Management cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 16.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,157 shares of the company’s stock after selling 794 shares during the period. Eli Lilly and Company makes up 2.3% of Peterson Wealth Management’s investment portfolio, making the stock its 16th biggest holding. Peterson Wealth Management’s holdings in Eli Lilly and Company were worth $3,433,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $27,000. Citizens National Bank Trust Department grew its holdings in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter valued at $40,000. Finally, TD Capital Management LLC grew its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.2%

Shares of LLY opened at $755.85 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market capitalization of $715.38 billion, a P/E ratio of 49.40, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The stock’s fifty day simple moving average is $741.52 and its 200 day simple moving average is $778.38. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $942.35.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend was Friday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 39.22%.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Guggenheim reduced their price target on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 30th. UBS Group reduced their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.